Research letter: BRAF-inhibitor induced panniculitis - A systematic review

To the Editor: BRAF-inhibitor induced panniculitis (BiP) is a rare cutaneous adverse reaction that clinically presents as tender nodules or plaques with accompanying systemic symptoms. These features pose a clinical challenge as they mimic infection or raise concern for a severe systemic inflammatory response that can require a change or cessation of oncologic therapy. 1 Blake T. Manahan M. Rodins K. Erythema nodosum – a review of an uncommon panniculitis. Dermatol Online J. 2014; 2022376https://doi.org/10.5070/D3204022376 Crossref Google Scholar ,2 Finelt N. Lulla R.R. Melin-Aldana H. et al. Bumps in the road: panniculitis in children and adolescents treated with vemurafenib. Pediatr Dermatol. 2017; 34: 337-341https://doi.org/10.1111/pde.13148 Crossref Google Scholar Despite being first reported in 2012, prior studies have been limited to retrospective case reports and small case series. 3 Piroth M. Frénard C. Eugène-Lamer J. Dreno B. Quéreux G. Hypodermite sous inhibiteur de BRAF et/ou inhibiteur de MEK: revue de la littérature à partir d’une nouvelle observation. Ann Dermatol Vénéréol. 2020; 147: 833-841https://doi.org/10.1016/j.annder.2020.07.013 Crossref Google Scholar We sought to characterize the clinical and histopathological features of the reported BiP as well as its clinical management and outcomes.